KLRS
カラリス・セラピューティクス
Kalaris Therapeutics Inc
プレマーケットデータ（自動更新なし）20日平均DV $483,326?
Earnings 2026-11-1152W high -65.7%52W low +72.9%Market cap $66MAvg volume 118K
Company Overview
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Earnings & Financials
Earnings actuals
| Period | EPS | Revenue | FCF |
|---|
| 2026 Q2 | -0.48 | $0 | -$11M |
| 2026 Q1 | -0.46 | $0 | -$13M |
| 2025 Q4 | -0.44 | $0 | -$9M |
| 2025 Q3 | -0.64 | $0 | -$12M |
| 2025 Q2 | -0.61 | $0 | -$15M |
| 2025 Q1 | -2.52 | $0 | -$7M |
| 2024 Q4 |
